Logo image of ATYR

ATYR PHARMA INC (ATYR) Stock Fundamental Analysis

NASDAQ:ATYR - US0021202025 - Common Stock

5.425 USD
+0.12 (+2.17%)
Last: 9/10/2025, 11:46:42 AM
Fundamental Rating

3

Overall ATYR gets a fundamental rating of 3 out of 10. We evaluated ATYR against 541 industry peers in the Biotechnology industry. While ATYR seems to be doing ok healthwise, there are quite some concerns on its profitability. ATYR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATYR had negative earnings in the past year.
In the past year ATYR has reported a negative cash flow from operations.
In the past 5 years ATYR always reported negative net income.
In the past 5 years ATYR always reported negative operating cash flow.
ATYR Yearly Net Income VS EBIT VS OCF VS FCFATYR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -65.63%, ATYR is in line with its industry, outperforming 40.48% of the companies in the same industry.
ATYR's Return On Equity of -89.03% is in line compared to the rest of the industry. ATYR outperforms 49.17% of its industry peers.
Industry RankSector Rank
ROA -65.63%
ROE -89.03%
ROIC N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ATYR Yearly ROA, ROE, ROICATYR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATYR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATYR Yearly Profit, Operating, Gross MarginsATYR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATYR has been increased compared to 1 year ago.
ATYR has more shares outstanding than it did 5 years ago.
ATYR has a better debt/assets ratio than last year.
ATYR Yearly Shares OutstandingATYR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATYR Yearly Total Debt VS Total AssetsATYR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.46 indicates that ATYR is not a great score, but indicates only limited risk for bankruptcy at the moment.
ATYR's Altman-Z score of 2.46 is fine compared to the rest of the industry. ATYR outperforms 69.32% of its industry peers.
ATYR has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ATYR has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ATYR outperforms 44.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.46
ROIC/WACCN/A
WACC9.59%
ATYR Yearly LT Debt VS Equity VS FCFATYR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 5.63 indicates that ATYR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.63, ATYR is in the better half of the industry, outperforming 60.26% of the companies in the same industry.
ATYR has a Quick Ratio of 5.63. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
ATYR has a better Quick ratio (5.63) than 60.63% of its industry peers.
Industry RankSector Rank
Current Ratio 5.63
Quick Ratio 5.63
ATYR Yearly Current Assets VS Current LiabilitesATYR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.09% over the past year.
The Revenue for ATYR has decreased by -100.00% in the past year. This is quite bad
Measured over the past years, ATYR shows a very negative growth in Revenue. The Revenue has been decreasing by -11.05% on average per year.
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.35%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A

3.2 Future

ATYR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.74% yearly.
Based on estimates for the next years, ATYR will show a very strong growth in Revenue. The Revenue will grow by 393.16% on average per year.
EPS Next Y15.85%
EPS Next 2Y7.57%
EPS Next 3Y28.53%
EPS Next 5Y39.74%
Revenue Next Year620.72%
Revenue Next 2Y1100.38%
Revenue Next 3Y828.13%
Revenue Next 5Y393.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATYR Yearly Revenue VS EstimatesATYR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATYR Yearly EPS VS EstimatesATYR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATYR. In the last year negative earnings were reported.
Also next year ATYR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATYR Price Earnings VS Forward Price EarningsATYR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATYR Per share dataATYR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ATYR's earnings are expected to grow with 28.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.57%
EPS Next 3Y28.53%

More info and screens

0

5. Dividend

5.1 Amount

ATYR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATYR PHARMA INC

NASDAQ:ATYR (9/10/2025, 11:46:42 AM)

5.425

+0.12 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners71.26%
Inst Owner ChangeN/A
Ins Owners2.21%
Ins Owner Change1.68%
Market Cap531.60M
Analysts83.53
Price Target20.55 (278.8%)
Short Float %29.42%
Short Ratio5.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.33%
Min EPS beat(2)-16.94%
Max EPS beat(2)12.28%
EPS beat(4)2
Avg EPS beat(4)3.69%
Min EPS beat(4)-16.94%
Max EPS beat(4)21.92%
EPS beat(8)5
Avg EPS beat(8)4.34%
EPS beat(12)9
Avg EPS beat(12)11.26%
EPS beat(16)10
Avg EPS beat(16)7.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.13%
PT rev (3m)12.33%
EPS NQ rev (1m)-12.83%
EPS NQ rev (3m)-8.12%
EPS NY rev (1m)-7.94%
EPS NY rev (3m)-10%
Revenue NQ rev (1m)-12.52%
Revenue NQ rev (3m)-62.5%
Revenue NY rev (1m)-11.11%
Revenue NY rev (3m)-51.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.1
P/tB 7.1
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.63%
ROE -89.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.63
Quick Ratio 5.63
Altman-Z 2.46
F-Score2
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)474.51%
Cap/Depr(5y)299.89%
Cap/Sales(3y)412.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.35%
EPS Next Y15.85%
EPS Next 2Y7.57%
EPS Next 3Y28.53%
EPS Next 5Y39.74%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A
Revenue Next Year620.72%
Revenue Next 2Y1100.38%
Revenue Next 3Y828.13%
Revenue Next 5Y393.16%
EBIT growth 1Y-12.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.5%
EBIT Next 3Y29.4%
EBIT Next 5Y31.91%
FCF growth 1Y-37.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.74%
OCF growth 3YN/A
OCF growth 5YN/A